Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

RTTNews | 1159 dni temu
Stocktwits
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.

Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. Prior to that, he was Head of the Immunology, Hepatology & Dermatology Global Development Unit at Novartis.

He launched his career in the pharmaceutical industry in 2004, in early clinical research at Bristol Myers-Squibb Co. and then at Schering-Plough Research Institute.

Tagi: TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 517 dni temu
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | 655 dni temu
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 664 dni temu
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 762 dni temu
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 846 dni temu
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | 855 dni temu
Taiwan Bourse May Extend Losing Streak

Taiwan Bourse May Extend Losing Streak

The Taiwan stock market has finished lower in four straight sessions, slumping more than 500 points or 2 percent along the way. The Taiwan Stock Exchange now sits just above the 24,000-point plateau and it may take further damage on Wednesday.
RTTNews | 8 minut temu
Narzędzia
Kalendarz ekonomiczny
Godziny handlu
Stopy procentowe
Kalendarz świąt
Rynek Forex
Zmienność na rynku Forex
Korelacja na rynku Forex
Wiadomości Forex
Analiza rynku Forex
Dane COT
Płynność
Kalkulatory Forex
Mapa termiczna Forex
Wskaźniki ekonomiczne
Społeczność
Społeczność
System
Najpopularniejsze systemy
Strategie
Konkursy
Wykresy Forex
Nastroje na rynku Forex
Wskaźnik prognozy
Recenzje
Brokerzy
Firmy proprietary trading
Usługi VPS
Dostawcy sygnałów
Usługi programistyczne EA
Programy partnerskie
Usługi brokerów PAMM
Usługi programu rabatowego
Platformy transakcyjne
Doradca
Giełdy kryptowalut
Kursy handlowe
Brokerzy
Spready na rynku Forex
Notowania brokera Forex
Swapy brokerów Forex
Wolumen brokera Forex
Akcje brokerów Forex
Informacja Prasowa
Platforma
Widgety
Funkcje
API
RSS
Stock Portfolio
Affiliate Software
Zaawansowane wykresy
Wsparcie
Najczęstsze pytania
Pomoc
Kontakt z nami
Zgłoś błąd!
O nas
Blog
© 2025 Myfxbook Ltd. Wszelkie Prawa Zastrzeżone.
Ostrzeżenie o wysokim ryzyku: handel walutami obcymi wiąże się z wysokim poziomem ryzyka, który może nie być odpowiedni dla wszystkich inwestorów. Dźwignia stwarza dodatkowe ryzyko i ryzyko straty. Zanim zdecydujesz się na handel walutami, dokładnie przemyśl swoje cele inwestycyjne, poziom doświadczenia i tolerancję ryzyka. Możesz stracić część lub całość początkowej inwestycji. Nie inwestuj pieniędzy, których nie możesz stracić. Zbadaj ryzyko związane z handlem walutami i zasięgnij porady niezależnego doradcy finansowego lub podatkowego, jeśli masz jakiekolwiek pytania. Wszelkie dane i informacje są dostarczane "tak, jak są" wyłącznie w celach informacyjnych i nie są przeznaczone do celów handlowych ani konsultacji. Wcześniejsze wyniki nie są wskaźnikiem przyszłych wyników.